VFA
ACAD icon

Virtus Fund Advisers’s Acadia Pharmaceuticals ACAD Stock Holding History

Virtus Fund Advisers’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$39.2K Buy
+2,135
New +$34.5K 0.12% 81
2017
Q4 		$993K Buy
+32,970
New +$1.05M 0.01% 287
2014
Q3 		– Sell
-6,723
Closed -$152K – 1159
2014
Q2 		$152K Buy
+6,723
New +$140K ﹤0.01% 1108

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Virtus Fund Advisers's ACAD Position: Q4 2024 in Review

Virtus Fund Advisers opened a new position in Acadia Pharmaceuticals (ACAD) in Q4 2024: 2,135 shares worth $39.2K. The stake represents 0.12% of the portfolio and ranks #81 among its holdings. This is a return to the name: Virtus Fund Advisers previously reported a position in ACAD as recently as Q4 2017.

Virtus Fund Advisers first reported a position in ACAD in Q2 2014 and has held it in 3 quarters since. The position peaked at $993K in Q4 2017. 295 funds tracked by Wall St. Rank hold ACAD as of Q4 2024.

  • Virtus Fund Advisers held 2,135 shares of Acadia Pharmaceuticals worth $39.2K as of Q4 2024.
  • Acadia Pharmaceuticals was a new Virtus Fund Advisers position in Q4 2024.
  • Acadia Pharmaceuticals made up 0.12% of Virtus Fund Advisers's portfolio in Q4 2024, its #81 holding.
  • Virtus Fund Advisers first reported a position in Acadia Pharmaceuticals in Q2 2014 and has held it in 3 quarters since.
  • Virtus Fund Advisers's Acadia Pharmaceuticals position peaked at $993K in Q4 2017.
  • 295 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2024.

Based on Virtus Fund Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.